Also known as: Copper peptide GHK-Cu, Glycyl-L-histidyl-L-lysine:copper(II), Copper tripeptide-1, Prezatide copper acetate
Half-life: ~30-60 minutes (plasma)
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys complexed with Cu2+) found in human plasma, saliva, and urine. It plays a fundamental role in tissue remodeling by stimulating collagen and elastin synthesis, promoting angiogenesis, recruiting immune cells to wound sites, and modulating inflammatory responses. Plasma levels of GHK-Cu decline significantly with age — from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — which correlates with the progressive loss of regenerative capacity observed in aging tissues.
The biological reach of GHK-Cu extends far beyond its initial cosmetic applications. A landmark 2012 study using the Connectivity Map (cMap) database revealed that GHK modulates the expression of over 4,000 human genes, representing roughly 6% of the human genome. Many of these genes are involved in tissue repair, antioxidant defense, stem cell differentiation, and extracellular matrix remodeling. The copper component is essential for full biological activity, serving as a cofactor for enzymes involved in collagen cross-linking (lysyl oxidase) and antioxidant defense (superoxide dismutase).
GHK-Cu is widely used in topical skincare products for anti-aging and wound healing, making it one of the most commercially successful peptides in the cosmetic industry. Subcutaneous injection for systemic effects is also practiced in the wellness community, though this route of administration has less clinical validation. The peptide is active at very low concentrations (nanomolar range), and its naturally occurring status in human physiology contributes to an excellent safety and tolerability profile.
GHK-Cu was first identified in 1973 by Dr. Loren Pickart while studying the differences between old and young human blood at the Biochemistry Department of the University of Washington. He discovered that a factor in young blood plasma promoted the synthesis of fibrinogen by old liver tissue, and this factor was identified as the tripeptide glycyl-L-histidyl-L-lysine complexed with copper (GHK-Cu). Subsequent work throughout the 1980s and 1990s established its roles in wound healing, skin remodeling, and collagen synthesis. The discovery that GHK-Cu modulates the expression of over 4,000 human genes (published in 2012) expanded understanding of its biological significance far beyond its initial cosmetic applications. It is now one of the most commercially successful peptides in the skincare industry.
GHK-Cu has an exceptional safety record spanning decades of use in topical skincare products. The peptide is naturally occurring in human plasma, contributing to its inherent biocompatibility. Topical application is extremely well tolerated, with only occasional mild skin irritation or sensitivity reported. Subcutaneous injection for systemic effects may cause injection site discomfort and an uncommon metallic taste. The copper component is present at physiological levels and does not accumulate to toxic concentrations. The peptide is active at very low nanomolar concentrations, meaning effective doses are far below any toxicity threshold.
Dose Range
1-2% concentration
Frequency
Once or twice daily
Duration
Ongoing
Dose Range
200-500 mcg
Frequency
Once daily
Duration
4-6 weeks
Dose Range
200-500 mcg
Frequency
Once daily near wound site
Duration
2-4 weeks
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
50 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2-5 mL
Half-Life
~30-60 minutes (plasma)
Molecular Weight
403.9 Da (free GHK) / 467.0 Da (GHK-Cu complex)
Store reconstituted vial refrigerated at 2-8°C. Use within 21 days. For SubQ use only. Topical GHK-Cu is available as ready-to-use creams and serums. The copper complex is essential for activity — plain GHK without copper is less effective.
FDA Status
Not FDA approved as a drug. Widely used as a cosmetic ingredient without requiring drug approval for topical formulations.
Legal Status
Regulated as a cosmetic ingredient in most countries. No drug approval required for topical use. Injectable form sold as research chemical.
USA
Not approved as drugWidely used as cosmetic ingredient, no drug approval needed for topical use
EU
Not approved as drugRegulated as cosmetic ingredient
UK
Not approved as drugCosmetic ingredient
Australia
Not approved as drugCosmetic ingredient
Russia
Not approved as drugAvailable as cosmetic ingredient
Canada
Not approved as drugCosmetic ingredient
Pickart L, Vasquez-Soltero JM, Margolina A
BioMed Research International (2015)
Comprehensive review of GHK-Cu mechanisms in skin regeneration, covering collagen synthesis, anti-inflammatory effects, and gene expression modulation.
View Study →Pickart L, Vasquez-Soltero JM, Margolina A
BioMed Research International (2014)
Landmark analysis using the Connectivity Map showing that GHK modulates expression of over 4,000 human genes, with patterns favoring tissue repair and health.
View Study →Pickart L, Margolina A
Oxidative Medicine and Cellular Longevity (2012)
Reviewed the antioxidant and anti-degenerative properties of GHK-Cu, documenting its decline with age and its potential as an anti-aging intervention.
View Study →Gastric pentadecapeptide with broad tissue-healing properties.
Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity.
Synthetic pineal tetrapeptide that activates telomerase and modulates melatonin production.
Synthetic melanocortin peptide with tanning, appetite-suppressive, and sexual function effects.
Track GHK-Cu and more with PinnyPeptide.
Sign Up to Track